Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings

Critical Care

Volumn 9, Issue SUPPL. 5, 2005, Pages

  Grounds, R Michael ^a   Bolan, Charles ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b Blood Services Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD DERIVATIVE; FRESH FROZEN PLASMA; OCTREOTIDE; PLACEBO; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SOMATOSTATIN; TERLIPRESSIN; VON WILLEBRAND FACTOR; WARFARIN;

BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BRAIN HEMORRHAGE; BRAIN INFARCTION; CHRONIC LIVER DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG MONITORING; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; EXPERIENCE; GASTROINTESTINAL HEMORRHAGE; GYNECOLOGIC SURGERY; HEART INFARCTION; HEART SURGERY; HEMATOLOGIC DISEASE; HEMOPHILIA; HEMOSTASIS; HUMAN; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER CIRRHOSIS; NEUROSURGERY; NONHUMAN; OBSTETRIC HEMORRHAGE; ORGAN TRANSPLANTATION; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSTATECTOMY; REVIEW; THREAT; THROMBOCYTE ANOMALY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

ANTICOAGULANTS; FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HUMANS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; WARFARIN;

EID: 31744436498     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc3783     Document Type: Review

References (52)

1. Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999, 354: 1879.
2. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, Lynn M: Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001, 51:431-438.
3. Hedner U, Erhardtsen E: Potential role for rFVIIa in transfusion medicine. Transfusion 2002, 42:114-124.
4. Roberts HR: Recombinant factor VIIa: a general hemostatic agent? Yes. J Thromb Haemost 2004, 2:1691-1694.
5. Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004, 104:3858-3864.
6. Ingerslev J: Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000, 26:425-432.
7. Poon MC: Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opin Hematol 2001, 8:312-318.
8. Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O, Steinberg DM, Rosove MH, O'Connell N, Lee CA, et al.: Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003, 101: 4783-4788.
9. Meijer K, Peters FT, van der MJ: Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood Coagul Fibrinolysis 2001, 12:211-213.
10. Poon MC, d'Oiron R: Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group. Blood Coagul Fibrinolysis 2000, Suppl 1:S55-S68.
11. Brenner B, Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L: Activated recombinant factor VII (rFVIIa/Novoseven) in the treatment of bleeding complications following hematopoietic stem cell transplantation (HSCT). Blood 2004, 104:321 a.
12. Hendriks HG, van der Maaten JM, de Wolf J, Waterbolk TW, Slooff MJ, van der MJ: An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001, 93:287-289.
13. Surudo T, Wojcicki M, Milkiewicz P, Czuprynska M, Lubikowski J, Jarosz K, Andrzejewska J, Zeair S, Sluzar T, Syczewska M, et al.: Rapid correction of prothrombin time after low-dose recombinant factor VIIA in patients undergoing orthotopic liver transplantation. Transplant Proc 2003, 35:2323-2325.
14. Lodge JPA, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, Garcia-Valdecasa JC, McAlister V, Mirza DF for the rFVIIa OLT Study Group: Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transplantation 2005, 11:973-979.
15. Planinsic RM: Safety and efficacy of single bolus dose of recombinant factor VIIa in patients undergoing orthotopic liver transplanation: a randomized multi-center study. Hepatology 2002, 36:660a.
16. Lodge JP, Jonas S, Oussoultzoglou E, Malago M, Jayr C, Cherqui D, Anthuber M, Mirza DF, Kuhlman L, Bechstein WO, et al.: Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial. Anesthesiology 2005, 102:269-275.
17. Lechner K, Niessner H, Thaler E: Coagulation abnormalities in liver disease. Semin Thromb Hemost 1977, 4:40-56.
18. Rutherford C, Frenkel E: Hemostatic disorders in liver disease. In Schiffs Diseases of the Liver. 8th Edition. Edited by Schiff ER, Sorrell MF, Maddrey WC. New York: Lippincott-Raven; 1999: 583-598.
19. Conteras M, Ala F, Greaves M, Jones J, Levin M, Machin S, Morgan C, Murphy W, Napier J, Thompson A: Guidelines for the use of fresh frozen plasma. Transfusion Med 1992, 2:57-63.
20. Diness V, Lund-Hansen T, Hedner U: Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res 1990, 59:921-929.
21. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U: The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998, 9:741-748.
22. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, Bech R, Hedner U, Schiff ER: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997, 113:1930-1937.
23. Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E: Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology 2002, 123:118-126.
24. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H: Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001, 36:1081-1085.
25. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez AJ, Fabricius S, Erhardtsen E, de Franchis R: Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004, 127:1123-1130.
26. Levi M, Bijsterveld NR, Keller TT: Recombinant factor VIIa as an antidote for anticoagulant treatment. Semin Hematol 2004, 41: 65-69.
27. Deveras RA, Kessler CM: Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002, 137:884-888.
28. Oefelein M, Colangelo L, Rademaker A, McVary K: Intra-operative blood loss and prognosis in prostate cancer patients undergoing radical retropubic prostatectomy. J Urol 1995, 154:447.
29. Friederich PW, Henny CP, Messelink EJ, Geerdink MG, Keller T, Kurth KH, Buller HR, Levi M: Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003, 361:201-205.
30. Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, Osman MM, Al Homaidhi A, Al Fagih M, Borum AR: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery, Blood Coagul Fibrinolysis 2000, Suppl 1:S121-S127.
31. Diprose P, Herbertson M, O'Shaughnessey D, Gill R: Factor VIIa for severe cardiac surgical bleeding. Crit Care 2002, Suppl 2:6.
32. Flynn J, Pajoumand M, Camp P, Jaharia M, Ramaiah C, Akers W: Recombinant factor VIIs for refractory bleeding following orthotopic heart transplantation. Ann Pharmacol 2004, 38:1639-1642.
33. Haymann C, Holtz H, Konertz W, Kox W, Spies C: Successful treatment of refractory bleeding with recombinant Factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002, 16:615-616.
34. Naik V, Mazer C, Latter D, Teitel J, Hare G: Successful treatment using recombinant factor VIIa for sever bleeding post cardiopulmonary bypass. Can J Anaesth 2003, 50:599-602.
35. Gerlach R, Marquardt G, Wissing H, Scharrer I, Raabe A, Seifert V: Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. Case report. J Neurosurg 2002, 96:946-948.
36. Park P, Fewel ME, Garton HJ, Thompson BG, Hoff JT: Recombinant activated factor VII for the rapid correction of coagulopathy in nonhemophilic neurosurgical patients. Neurosurgery 2003, 53:34-38.
37. Raobaikady R, Redman J, Ball JA, Maloney G, Grounds RM: Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 2005, 94:586-591.
38. Rosencher N, Kerkkamp HE, Macheras G, Munuera LM, Menichella G, Barton DM, Cremers S, Abraham IL: Orthopedic Surgery Transfusion Hemoglobin European Overview (OSTHEO) study: blood management in elective knee and hip arthroplasty in Europe. Transfusion 2003, 43:459-469.
39. Danilos J, Goral A, Paluszkiewicz P, Przesmycki K, Kotarski J: Successful treatment with recombinant factor VIIa for intractable bleeding at pelvic surgery. Obstet Gynecol 2003, 101:1172-1173.
40. Bouwmeester FW, Jonkhoff AR, Verheijen RH, van Geijn HP: Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstet Gynecol 2003, 101:1174-1176.
41. Price G, Kaplan J, Skowronski G: Use of recombinant factor VIIa to treat life-threatening non-surgical bleeding in a post-partum patient. Br J Anaesth 2004, 93:298-300.
42. Ahonen J, Jokela R: Recombinant factor VIIa for life-threatening post-partum haemorrhage. Br J Anaesth 2005, 94:592-595.
43. Gielen-Wijffels SE, van Mook WN, van der GS, Ramsay G: Successful treatment of severe bleeding with recombinant factor VIIa after kidney transplantation. Intensive Care Med 2004, 30: 1232-1234.
44. O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy DF, Laffan MA, Smith OP: Recombinant FVIIa in the management of uncontrolled hemorrhage. Transfusion 2003, 43:1711-1716.
45. Hay CR, Negrier C, Ludlam CA: The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multi-centre study. Thromb Haemost 1997, 78:1463-1467.
46. Mayer SA, Brun NC, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Safety and feasibility of recombinant factor VIIa for acute intracerebral hemorrhage. Stroke 2005, 36:74-79.
47. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352: 777-785.
48. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y, for the NovoSeven Trauma Study Group: Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients. J Trauma 2005, 59: 8-18.
49. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C: Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004, 44:1325-1331.
50. Sorensen B, Ingerslev J: Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 2004, 41:140-144.
51. Hendriks HG, Meijer K, de Wolf JT, Porte RJ, Klompmaker IJ, Lip H, Slooff MJ, van der MJ: Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002, 13: 309-313.
52. Sallah S, Husain A, Nguyen NP: Recombinant activated factor VII in patients with cancer and hemorrhagic disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2004, 15: 577-582.